Additional Opportunities for Funding and Collaboration with GSK 

 

While applications submitted in response to this FOA may propose research in any disease or health area that falls within the broad areas of genetic and/or environmental contributors to disease or health research, there are also specific areas of interest to GlaxoSmithKline as part of the Africa NCD Open Lab initiative who are participating in this call.

GSK’s aim is to fund rigorous, high quality research that will address the application of genomics to disease mechanisms, epidemiology, pathophysiology and aetiology, or prevention and treatment of primary disease and associated complications in at least one of the following priority non-communicable disease (NCD) areas: cardiovascular disease, oncology, chronic respiratory disease, chronic kidney disease and diabetes. Successful proposals must demonstrate significant potential to scale up into further research.

GSK funding will be restricted to projects led from within the following countries; Cameroon, Cote D’Ivoire, Ethiopia, Ghana, Gambia, Kenya, Malawi, Nigeria, Senegal, South Africa, Tanzania & Uganda. South-South partnerships are actively encouraged and countries outside of this list can be included as sub-sites. Proposals focusing on drug development and public health interventions are out of scope. Details about the conditions for GSK awards can be found here

GSK awardees will largely be expected to follow the principles of H3Africa relating to data sharing, collaboration and best practice in genetics research, but at all times will comply with the requirements of their particular collaboration agreement with GSK. GSK awards will be made in GBP.

Where appropriate GSK will also provide scientific expertise through training and skills transfer to support project delivery.